Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GGTA1 KO Thymokidney

Other · developed by United Therapeutics

Phase 1/2 Most advanced trial
UTHR Developer
1 Registered trials

What is GGTA1 KO Thymokidney?

GGTA1 KO Thymokidney is a porcine kidney carrying an intentional genomic alteration, transplanted together with a thymic tissue autograft, for xenotransplantation. It is studied in end-stage renal disease patients who need a kidney transplant.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Renal & urology
Developer
United Therapeutics (UTHR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07224763 Phase 1/2 ESRD (End-Stage Renal Disease) Recruiting UTHR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ESRD (End-Stage Renal Disease)Kidney TransplantationXenotransplantation

More from United Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the UTHR page.

Follow UTHR, the company behind GGTA1 KO Thymokidney

See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

UTHR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.